 Home > Encyclopedia > Darapladib

Darapladib

Darapladib structure

CAS No:
356057-34-6
Formula:
C36H38F4N4O2S
Chemical Name:
Darapladib
Synonyms:
1H-Cyclopentapyrimidine-1-acetamide,N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methyl]-;N-[2-(Diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methyl]-1H-cyclopentapyrimidine-1-acetamide;1-[[[N-[2-(Diethylamino)ethyl]-N-[4-[4-(trifluoromethyl)phenyl]benzyl]amino]carbonyl]methyl]-2-(4-fluorobenzylthio)-5,6-trimethylenepyrimidin-4-one;SB 480848;SB 435445;Darapladib
Categories:
Biochemical Engineering > Inhibitors

Description

Darapladib is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with IC50 of 0.25 nM.

Darapladib is a substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2), an important regulator of lipid metabolism and inflammation that circulates with lipoprotein particles and is carried into the arterial wall with low-density lipoprotein particles during the progression of atherosclerosis.

Darapladib Basic Attributes

Molecular Weight：

666.79

Exact Mass：

666.77

UNII：

UI1U1MYH09

DSSTox ID：

DTXSID70189073

NCI Thesaurus Code：

C72985

Characteristics

PSA：

81.5

XLogP3：

Density：

1.3±0.1 g/cm3

Boiling Point：

741.002°C at 760 mmHg

Flash Point：

401.9±35.7 °C

Refractive Index：

1.594

Safety Information

Precautionary statement(s)：

P273, P280, P305+P351+P338, P310, P391, P501

Hazard Statements：

H318

GHS Classification：

|Danger|H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation]|P273, P280, P305+P351+P338, P310, P391, and P501|Aggregated GHS information provided by 3 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Drug Indication：

Investigated for use/treatment in atherosclerosis.

MeSH：

Compounds that inhibit or block the activity of a PHOSPHOLIPASE A2 enzyme. (See all compounds classified as Phospholipase A2 Inhibitors.)

Mechanism of Action：

Darapladib is a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzymatic upstream mediator of inflammatory processes. Evidence from experimental settings show that the breakdown products from oxidized low density lipoprotein C (LDL-C)such as lysophosphatidylcholine species and oxidized nonesterified fatty acids are pro-inflammatory and pro-apoptotic. These products are suspected to cause athlerosclerosis progression and plaque vulnerability, which leads to increased risk of cardiovascular problems.

MeSH Entry Terms：

darapladib

Darapladib Use and Manufacturing

Treatment of atherosclerosis.

Computed Properties

Molecular Weight:666.8
XLogP3:7
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:13
Exact Mass:666.26516029
Monoisotopic Mass:666.26516029
Topological Polar Surface Area:81.5
Heavy Atom Count:47
Complexity:1120
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of Darapladib

HANGZHOU LEAP CHEM CO., LTD. Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives

Darapladib

CAS No.: 356057-34-6

Content: 99.00%

Inquiry